Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: A randomized, double-blind, placebo-controlled study conducted in Japan (sunrise study)

Journal of Clinical Psychiatry

Volumn 76, Issue 2, 2015, Pages 181-188

  Higuchi, Susumu ^a  

^a KURIHAMA NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; GAMMA GLUTAMYLTRANSFERASE; PHOSPHATE; PLACEBO; TRIACYLGLYCEROL; ALCOHOL; TAURINE;

ABDOMINAL SWELLING; ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ATRIOVENTRICULAR BLOCK; COGNITIVE THERAPY; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GROUP THERAPY; HUMAN; ICD-10; JAPAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL COUNT; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VOMITING; WITHDRAWAL SYNDROME; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; LONG TERM CARE; MIDDLE AGED; SUBSTANCE WITHDRAWAL SYNDROME;

ADULT; AGED; ALCOHOLISM; DOUBLE-BLIND METHOD; ETHANOL; FEMALE; HUMANS; JAPAN; LONG-TERM CARE; MALE; MIDDLE AGED; SUBSTANCE WITHDRAWAL SYNDROME; TAURINE;

EID: 84928415494     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.13m08940     Document Type: Conference Paper

References (45)

1. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004;28(1):51-63. doi:10.1097/01.ALC.0108656.81563.05 PubMed
2. Dranitsaris G, Selby P, Negrete JC. Meta-analyses of placebo-controlled trials of acamprosate for the treatment of alcohol dependence: impact of the combined pharmacotherapies and behavior interventions study. J Addict Med. 2009;3(2):74-82. doi:10.1097/ADM.0b013e318182d890 PubMed
3. Koeter MW, van den Brink W, Lehert P. Effect of early and late compliance on the effectiveness of acamprosate in the treatment of alcohol dependence. J Subst Abuse Treat. 2010;39(3):218-226. doi:10.1016/j.jsat.2010.06.02 PubMed
4. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;8(9):CD004332. PubMed
5. Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275-293. doi:10.1/j.1360-043.2012.04054.x PubMed
6. Anton RF. Pharmacologic approaches to the management of alcoholism. J Clin Psychiatry. 2001;62(suppl 20):11-17. PubMed
7. De Witte P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addict Behav. 2004;29(7):1325-1339. doi:10.1016/j.adbeh.204.06.020 PubMed
8. De Witte P, Littleton J, Parot P, et al. Neuroprotective and abstinencepromoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs. 2005;19(6):517-537 .doi:10.2165/023210-20519060-04 PubMed
9. Mann K, Kiefer F, Spanagel R, et al. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res. 2008;32(7):1105-1110. doi:10.1/j.1530-027.208.0690.x PubMed
10. Kiefer F, Mann K. Acamprosate: how, where, and for whom does it work? mechanism of action, treatment targets, and individualized therapy. Curr Pharm Des. 2010;16(19):2098-2102. doi:10.2174/138161210791516341 PubMed
11. Witkiewitz K, Saville K, Hamreus K. Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Ther Clin Risk Manag. 2012;8:45-53. doi:10.2147/TCRM.S23184 PubMed
12. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217-238. doi:10.1038/np.209.10 PubMed
13. Garbutt JC. The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat. 2009;36(1):S15-S23, quiz S24-S25. PubMed
14. Litten RZ, Egli M, Heilig M, et al. Medications development to treat alcohol dependence: A vision for the next decade. Addict Biol. 2012;17(3):513-527.
15. Zernig G, Fabisch K, Fabisch H. Pharmacotherapy of alcohol dependence. Trends Pharmacol Sci. 1997;18(7):229-231. doi:10.1016/S0165-6147(97)01075-4 PubMed
16. Lingford-Hughes AR, Welch S, Nutt DJ; British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2004;18(3):293-335. doi:10.17/026981040180321 PubMed
17. National Institutes of Health. Helping Patients Who Drink Too Much. A Clinician's Guide Updated 2008. Bethesda, MD: NIH Publication; 2008:1-9.
18. Higuchi S. Study on the Alcohol Dependency Treatment System. Assigned Research Report Funded by Health and Labour Sciences Research Grants [in Japanese]. Tokyo, Japan: Comprehensive Research on Disability Health and Welfare; 2001.
19. Mason BJ, Goodman AM, Chabac S, et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebocontrolled trial: The role of patient motivation. J Psychiatr Res. 2006;40(5):383-393.doi:10.1016/j.jpsychires.206.02.02 PubMed
20. Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: A 90-day placebocontrolled dose-finding study. Br J Psychiatry. 1997;171(1):73-77.doi:10.192/bjp.171.1.73 PubMed
21. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53(8):673-680.doi:10.101/archpsyc.196.01830802306 PubMed
22. Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30(2):239-247. PubMed
23. Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: A double-blind placebo-controlled study in Spain. Alcohol Alcohol. 2001;36(5):413-418.doi:10.1093/alcalc/36.5.413 PubMed
24. Geerlings PJ, Ansoms C, van den Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res. 1997;3(3):129-137. doi:10.159/025916
25. Ladewig D, Knecht T, Leher P, et al. Acamprosate-A stabilizing factor in long-term withdrawal of alcoholic patients[article in German]. Ther Umsch. 1993;50(3):182-188. PubMed
26. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction. 1997;92(11):1537-1546.doi:10.1/j.1360-043.197.tb02873.x PubMed
27. Tempesta E, Janiri L, Bignamini A, et al. Acamprosate and relapse prevention in the treatment of alcohol dependence: A placebo-controlled study. Alcohol Alcohol. 2000;35(2):202-209.doi:10.1093/alcalc/35.2.202 PubMed
28. Chick J, Howlett H, Morgan MY, et al. United Kingdom Multicentre Acamprosate Study (UKMAS): A 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000;35(2):176-187.doi:10.1093/alcalc/35.2.176 PubMed
29. Barrias JA, Chabac S, Ferreira L, et al. Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatria Clin. 1997;18(2):149-160.
30. Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study. Alcohol Clin Exp Res. 1998;22(3):573-579.doi:10.1/j.1530-027.198.tb04295.x PubMed
31. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996;347(9013):1438-1442.doi:10.1016/S0140-6736(96)91682-7 PubMed
32. Booth BM, Cook CA, Blow FC, et al. Utilization of outpatient mental health services after inpatient alcoholism treatment. J Ment Health Adm. 1992;19(1):21-30.doi:10.107/BF02521304 PubMed
33. Fuller RK, Hiller-Sturmhöfel S. Alcoholism treatment in the United States. An overview. Alcohol Res Health. 1999;23(2):69-77. PubMed
34. Mann K, Lemenager T, Hoffmann S, et al; PREDICT Study Team. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013;18(6):937-946.doi:10.1/adb.12012 PubMed
35. Namkoong K, Lee BO, Lee PG, et al. Acamprosate in Korean alcoholdependent patients: A multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol. 2003;38(2):135-141. doi:10.1093/alcalc/ag038 PubMed
36. Anton RF, O'Malley SS, Ciraulo DA, et al; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA. 2006;295(17):2003-2017. doi:10.101/jama.295.17.203 PubMed
37. Morley KC, Teesson M, Reid SC, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101(10):1451-1462. doi:10.1/j.1360-043.206.015.x PubMed
38. Spanagel R, Kiefer F. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci. 2008;29(3):109-115. doi:10.1016/j.tips.207.12.05 PubMed
39. Project Match Research Group. Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol. 1997;58(1):7-29. PubMed
40. Noda T, Imamichi H, Kawata A, et al. Long-term outcome in 306 males with alcoholism. Psychiatry Clin Neurosci. 2001;55(6):579-586. doi:10.1046/j.140-1819.201.0909.x PubMed
41. Collins GB, McAllister MS, Adury K. Drug adjuncts for treating alcohol dependence. Cleve Clin J Med. 2006;73(7):641-644, 647-648, 650-651 passim. doi:10.3949/cjm.73.7.641 PubMed
42. Jung YC, Namkoong K. Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention. Yonsei Med J. 2006;47(2):167-178. doi:10.349/ymj.206.47.2.167 PubMed
43. National Treatment Agency for Substance Misuse. Review of the effectiveness of treatment for alcohol problems. http://www.nta.nhs.uk/uploads/nta-review-of-the-effectiveness-of-treatment-for-alcohol-problems-fullreport-2006-alcohol2.pdf. Accessed October 18, 2013.
44. National Institute for Health and Clinical Excellence (NICE). Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. http://www.nice.org.uk/guidance/cg115. Updated February 2011. Accessed November 19, 2014.
45. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: A clinical review. J Clin Psychiatry. 2001;62(suppl 20):42-48. PubMed